Eversana Announces Strategic Partnership With Roivant Sciences to Advance Commercialization Services and Predictive Analytics for Healthcare

Under a multi-year partnership, EVERSANA will become the preferred provider of commercialization services for Roivant

EVERSANA will expand existing collaborations with Roivant technology platforms, including deploying Alyvant’s salesforce app to enhance results for EVERSANA clients

EVERSANA and Roivant will collaborate on launch strategies for multiple investigational medicines across the Roivant family of companies

Roivant Sciences named EVERSANA, the pioneer of next-generation commercial services to the global life sciences industry, a preferred provider of commercial services worldwide. Under the agreement, EVERSANA and Roivant will partner on opportunities to improve the access, affordability and adherence of innovative therapies developed by Roivant. In addition, EVERSANA and Roivant will expand existing partnerships around multiple Roivant technology platforms, including deploying Alyvant’s salesforce app to enhance results for EVERSANA clients.

Roivant has a diverse pipeline of investigational drugs across its family of companies. In addition to its biopharmaceutical subsidiaries, Roivant also builds technology-focused platforms aimed at improving the process of developing and commercializing medicines.

Recommended AI News: Adlumin Goes Live In Amazon Web Services (AWS) Marketplace

EVERSANA, which is currently managing the launch of multiple pharmaceutical and digital therapies, offers a fully integrated commercial services platform designed to solve global pricing, access, reimbursement, real-world evidence, adherence and product delivery challenges in the life sciences sector.

“We are thrilled to collaborate with EVERSANA on deploying innovative technologies and nontraditional approaches to improve the delivery of medicines to patients – within and beyond our own pharmaceutical portfolio,” said Ben Zimmer, President of Roivant Health.

Recommended AI News: Paessler Launches Industrial It Monitoring Solution

“Roivant shares our view that traditional approaches to commercialization services leave too much value on the table. Our patients, providers and payers need a more comprehensive approach to life sciences services, propelled by bolder strategies and integrated superior performance that is optimized by a predictive platform of data and analytics at each step of the patient and product journeys,” said Jim Lang, CEO, EVERSANA.

Recommended AI News: Ekinops Chosen By Swisscom For Access Network Virtualization Software